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Abstract 1 
Objective: To identify the most cost-effective policy for detection and management of fetal 2 
macrosomia in late-stage pregnancy. 3 
Design: Health economic simulation model. 4 
Setting: All English NHS antenatal services. 5 
Population: Nulliparous women in the third trimester treated within the UK NHS. 6 
Methods: A health economic simulation model was used to compare long-term maternal-fetal health 7 
and cost outcomes for two detection strategies (universal ultrasound scanning at approximately 36 8 
weeks gestational age versus selective ultrasound scanning), combined with three management 9 
strategies (planned caesarean section versus induction of labour versus expectant management) of 10 
suspected fetal macrosomia. Probabilities, costs and health outcomes were taken from literature. 11 
Main Outcome Measures: Expected costs to the NHS and Quality-adjusted life years (QALYs) gained 12 
from each strategy, calculation of net benefit and hence identification of most cost-effective strategy. 13 
Results: Compared to selective ultrasound, universal ultrasound increased QALYs by 0.0038 (95% CI: 14 
0.0012, 0.0076), but also costs by £123.5 (95% CI: 99.6, 149.9). Overall, the health gains were too small 15 
to justify the cost increase. The most cost-effective policy was selective ultrasound coupled with 16 
induction of labour where macrosomia was suspected. 17 
Conclusions: The most cost-effective policy for detection and management of fetal macrosomia is 18 
selective ultrasound scanning coupled with induction of labour for all suspected cases of macrosomia. 19 
Universal ultrasound scanning for macrosomia in late-stage pregnancy is not cost-effective. 20 
Funding: National Institute for Health Research (NIHR) 21 
Keywords: Macrosomia, ultrasound, screening, economic modelling, third-trimester, pregnancy, 22 
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Tweetable abstract 1 
Universal late-pregnancy ultrasound screening for fetal macrosomia is not warranted. 2 
  3 
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Introduction 1 
The detection and management of macrosomia, i.e. excessive fetal growth, poses a challenge to 2 
maternity care. Macrosomia is associated with increased perinatal mortality and morbidity, e.g. 3 
shoulder dystocia leading to brachial plexus injury (BPI), as well as increased risk of maternal 4 
morbidity. 1-3 The definition of macrosomia varies, but is usually defined as a birth weight above either 5 
4000g or 4500g. It is differentiated from, but closely related to, the concept of large for gestational 6 
age (LGA) which is a relative measure: weight greater than the 90th percentile for a given gestational 7 
age.1, 4 Macrosomia can only be definitively diagnosed by weighing the infant following delivery. 8 
However, ultrasound scans can be used to estimate the fetal weight antenatally, although this 9 
approach is known to have low predictive value. 1 There is no general agreement on how to manage 10 
macrosomia if suspected following ultrasound.1, 4-6 Possible interventions include scheduling an 11 
elective caesarean section (CS), or early induction of labour. However, uncertainty regarding the 12 
clinical effectiveness of these interventions persists.1, 5 Furthermore, if given without clinical need, 13 
intervention may cause unnecessary harm, e.g. neonatal respiratory morbidity, and increased 14 
maternal risks of caesarean section.1, 4, 7, 8 15 
There is currently no national programme that couples screening for macrosomia with a proven, 16 
disease modifying intervention.4, 9 Currently, clinical examination of third-trimester pregnancies does 17 
not routinely include ultrasound, but women may be selected for ultrasound scanning following 18 
clinical suspicion of macrosomia (selective ultrasound). An alternative approach would be to 19 
prospectively scan all women for macrosomia (universal ultrasound) at around 36 weeks gestational 20 
age, but whether the benefits of such an approach would justify the increased costs and risk of harmful 21 
interventions is unclear. A previous study showed only modest health benefits from universal 22 
ultrasound, and the cost for every prevented severe adverse outcome was too high to justify routine 23 
scanning.10 However, this study is now over 20 years old and only considered one management 24 
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strategy for suspected macrosomia: delivery by planned CS. Following recent research and changes in 1 
obstetric care, we sought to re-evaluate the case for universal ultrasound screening for macrosomia.11 2 
In this study, we identify the most cost-effective strategy for detection and management of 3 
macrosomia in late pregnancy among nulliparous women in the setting of the UK NHS.  4 
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Methods 1 
Model structure 2 
The scope of this model was limited to screening for macrosomia rather than any other complication 3 
of pregnancy. To compare the cost-effectiveness of different policies for detection and management, 4 
we constructed a decision tree simulation model using R (Figure 1).12-14 Each policy had two 5 
components: one for the detection of macrosomia, and one for the management of suspected 6 
macrosomia. The detection strategy was either universal ultrasound in the third trimester (around 36 7 
weeks gestational age), or selective ultrasound, i.e. clinical examination through abdominal palpation, 8 
where ultrasound would be offered only where macrosomia was suspected. The management 9 
strategy for suspected macrosomia was either to schedule an elective caesarean section (Planned CS), 10 
induce labour (Induction), or expectant management awaiting spontaneous labour onset. If 11 
macrosomia was not suspected, expectant management was used. There are therefore a total of six 12 
discrete detection/management policies. 13 
The model structure for detection and management for macrosomia is shown in Figure 1 (part A). Four 14 
different screening statuses were possible: true positives (TP), false negatives (FN), false positives (FP), 15 
and true negatives (TN). The likelihood of each state was driven by the sensitivity and specificity of the 16 
test used for detection, as well as the prevalence of macrosomia. When macrosomia was suspected, 17 
the pregnancy was managed according to the management strategy being evaluated: planned 18 
caesarean section, induction of labour, or expectant management. If macrosomia was not suspected, 19 
it was assumed vaginal delivery would be attempted, with a risk of emergency caesarean section. To 20 
accurately capture the consequences of a false positive diagnosis of macrosomia, we distinguished 21 
between expectant management when macrosomia was suspected or not suspected; suspected 22 
macrosomia increased the risk of caesarean delivery following expectant management.8 23 
Five neonatal delivery outcomes were possible: No complications, Respiratory morbidity, Shoulder 24 
dystocia, Other acidosis (i.e. acidosis not induced by shoulder dystocia), and perinatal mortality. Their 25 
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respective likelihoods were affected by both screening and management strategies (see below). The 1 
fetal delivery outcomes were then extrapolated into long-term costs and quality-adjusted life years 2 
(QALYs) through the model shown in Figure 1.  3 
Model inputs 4 
Probabilities 5 
For each adverse outcome (respiratory morbidity, shoulder dystocia, other acidosis, and mortality), 6 
we obtained the baseline risk of that outcome; i.e. the risk if non-large and non-induced neonate with 7 
vaginal delivery. We then multiplied this risk with the relative risk of each present risk factor 8 
(macrosomia, induction, delivery through elective caesarean section, and delivery through emergency 9 
caesarean section). For technical details, see Appendix S1. 10 
Model input parameters are shown in supplementary material Table S1. Values were identified from 11 
literature by AM and DW, prioritising values from systematic reviews and UK data where possible. 12 
Ideally, every input should be based upon a systematic review, reflecting current state of knowledge. 13 
However, resources only permitted identification of suitable data, rather than performing a meta-14 
analysis. For this reason, sources that provided a distribution for the likely parameter values were 15 
prioritized, so that the overall uncertainty associated with this parameter could be assessed through 16 
probabilistic sensitivity analysis.15 Where multiple sources were available the source was chosen by 17 
consensus or through arbitration by GS,.. Where no credible values for a model parameter could be 18 
identified from the literature, AM and GS identified lower and upper limits to the value the parameter 19 
could reasonably assume; the model then sampled input values from this interval using a uniform 20 
distribution. 21 
Macrosomia was defined as estimated fetal weight (EFW) ≥ 90th percentile, i.e. the same as large for 22 
gestational age (LGA). The sensitivity and specificity for detection of macrosomia, as well as the 23 
prevalence of macrosomia, were taken from the POP study, a prospective cohort study of unselected 24 
nulliparous women where all women had fetal biometry at 36 weeks of gestational age (wkGA), where 25 
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the result of the scan was blinded.16, 17 Using data from this study allowed for a comparison between 1 
diagnostic performance of universal and selective ultrasound. Detection with selective ultrasound was 2 
based upon clinical suspicion before 36 wkGA following measurement of symphyseal-fundal height, 3 
and confirmed with a clinically indicated ultrasound.17 The baseline risk of each adverse outcome was 4 
defined as the risk for a normal size neonate, where labour was not induced and resulted in a vaginal 5 
delivery. We used odds ratios from the literature when directly presented, otherwise we calculated 6 
unadjusted odds ratios from prevalence data.18 Odds ratios were assumed log-normally distributed.  7 
Long-term outcomes 8 
Unit costs and health state utilities are shown in supplementary material Table S1. The average costs 9 
for induction of labour and respiratory morbidity were calculated from the NHS reference costs (see 10 
Appendix S2).19 Brachial Plexus Injury (BPI) could be either transient or permanent, this was modelled 11 
using Beta distribution.20 We assumed that BPI would require the same resource usage as reported by 12 
Culligan et al., and obtained the costs for these resources from the NHS reference costs (see Appendix 13 
S2).19, 21 We assumed that all cases of non-severe asphyxia would be treated in the neonatal unit for 14 
1-3 days, but that no additional costs would accrue beyond this. To estimate the long-term outcomes 15 
from ‘Severe anoxic brain damage’, we made the simplifying assumption that the costs, consequences 16 
and likelihood mirrored those of neonatal encephalopathy (NE). Evidence shows that providing 17 
therapeutic hypothermia reduces the likelihood of adverse outcomes from NE and this treatment is 18 
routine clinical practice.22, 23 We assumed that all cases of NE would receive therapeutic hypothermia, 19 
and adjusted costs and consequences from NE accordingly; for this reason, we reduced the likelihood 20 
of mortality and severe anoxic brain damage following asphyxia by 11.1%.24 The costs from severe 21 
anoxic brain damage included hospital and community care costs for all survivors in the cooled group 22 
as reported by Regier et al. (2010)22; the hospital costs were for the first 18 months only, but we 23 
assumed that the community care costs post discharge would accrue annually for the entirety of the 24 
model’s time horizon. We made the simplifying assumption that the cost of death would be the same 25 
regardless of reason. 26 
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Quality-adjusted life years (QALYs) combine the utility of a health-state with its duration, where utility 1 
is based upon quality of life (QOL). QOL can be expressed as a numeric value, where 1 is equivalent to 2 
full health and 0 equivalent to death.25, 26 Maternal QALYs were based upon the mode of delivery, and 3 
QOL weights were obtained from Petrou et al.27; these QOL weights were derived using EQ-5D, as 4 
recommended by NICE.28, 29 For surviving infants, we calculated the expected QALYs based upon the 5 
assumptions above; per definition fetal QALYs were zero for death. 6 
Model scope 7 
The expected cost and QALYs gained from six different policies for screening and management of 8 
macrosomia were calculated over a 20-year time horizon. Costs and QALYs were discounted by 3.5% 9 
annually, as recommended by NICE.29 Probabilistic sensitivity analysis (PSA) was used in order to 10 
capture the overall effect of uncertainty in the model parameters. Costs associated with potential 11 
litigation claims or potential effects upon subsequent pregnancies were not included. Results were 12 
based upon 100,000 simulations and results presented as expected values, incremental cost and 13 
QALYs, incremental cost-effectiveness ratios (the ratio of incremental cost to incremental QALYs; 14 
ICER), and net benefits (defined as QALYs multiplied by the willingness to pay (WTP) for a QALY less 15 
the cost). The WTP per QALY threshold was assumed to be £20,000 (the lower of NICE’s stated 16 
thresholds).29 Decision uncertainty is illustrated via cost-effectiveness acceptability curves (CEACs).29, 17 
30 The model’s sensitivity towards key parameters was explored through one-way sensitivity analysis 18 
(see Appendix S4). Given the paucity of data relating to maternal quality of life, an additional scenario 19 
was conducted including neonatal QALYs alone. Further scenarios explored the impact of assigning 20 
zero additional costs for induction of labour, and assuming that induction of labour is cost saving (due 21 
to reduced antenatal assessments). .29, 30 All costs are from the third-party payer (i.e. NHS) perspective, 22 
and the price year is 2016/17. Costs from other years were inflated to the price year of the analysis 23 
using the hospital & community health services (HCHS) index.31 As this is a secondary analysis / 24 
synthesis of existing data, no patients or the public were involved in the study.  25 
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Results 1 
The expected costs and quality-adjusted life years (QALY) for each policy are shown in Table 1. The 2 
least expensive option is selective ultrasound with expectant management and the most expensive 3 
option is universal ultrasound with planned CS. The least effective option (in terms of QALYs gained) 4 
is universal ultrasound with planned CS and the most effective option is universal ultrasound with 5 
induction of labour. Three strategies (selective US + planned CS, universal ultrasound + expectant 6 
management, and universal ultrasound + planned CS) are dominated or extended-dominated by other 7 
strategies. Taking into account the balance between costs and outcomes (and with a WTP threshold 8 
of £20,000 per QALY), the most cost-effective strategy is selective ultrasound plus induction of labour 9 
where macrosomia is suspected. Although universal ultrasound plus induction is expected to yield 10 
marginally greater QALYs (+0.002), the added cost (+£113) yields an ICER of £52,719. This is above the 11 
threshold and is not, therefore, cost-effective. The expected distribution of mode of delivery and 12 
neonatal delivery outcomes are detailed in Appendix S3 and Table S2. 13 
We investigated the value of universal ultrasound alone, by comparing the results for universal and 14 
selective ultrasound when using the same management strategy. When the management strategy 15 
was planned CS, universal ultrasound was associated with a cost increase of £123.5 (95% Confidence 16 
interval: £99.6, £149.9), and QALY increase of 0.0038 (95% CI: 0.0012, 0.0076). The ICER for this 17 
strategy was £35,755 (95% CI: £15,962, £98,506). The comparable ICERs for induction of labour and 18 
expectant management were even higher, indicating that universal ultrasound screening is unlikely to 19 
be cost-effective. 20 
The probability of each policy being the most cost-effective as a function of the WTP-threshold is 21 
shown by the CEAC (Figure 2). Selective ultrasound coupled with induction of labour for suspected 22 
macrosomia had the greatest chance of being cost-effective for NICE’s recommended thresholds of 23 
£20,000 to £30,000 per QALY.29 Sensitivity analysis showed that the choice of policy was most sensitive 24 
towards the specificity of ultrasound (both universal and selective), maternal quality of life (QOL) for 25 
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delivery through elective CS, and the prevalence of macrosomia (See Appendix S4 and Table S3). 1 
Although influential, the cost of ultrasound screening alone appears insufficient to determine whether 2 
universal screening would be cost-effective; analysis showed that if other parameters remained 3 
unchanged, universal ultrasound would only be cost-effective if the cost of ultrasound was £26.56 or 4 
lower. 5 
Excluding maternal QALYs from the analysis, selective ultrasound plus planned CS was the preferred 6 
management strategy, compared with induction of labour, under the base case (Table S4). No other 7 
assumptions tested in the alternative scenarios affected the conclusions; selective ultrasound with 8 
induction of labour remained the preferred strategy for all other scenarios.  9 
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Discussion 1 
Main findings 2 
This study has compared the cost-effectiveness of different policies for detection and management of 3 
fetal macrosomia in late-stage pregnancy among nulliparous women. The most cost-effective policy 4 
was selective ultrasound coupled with induction of labour for all cases of suspected fetal macrosomia. 5 
Although universal ultrasound scanning leads to higher identification of suspected macrosomia, this 6 
only translates into modest improvements of overall long-term health outcomes which are not 7 
justified by the added cost of the ultrasound scan. The expected health gain (0.003 QALYs over 20 8 
years) is small due to both the low risk of severe neonatal outcomes resulting from undiagnosed 9 
macrosomia and the risk of interventions themselves causing harm.   10 
Where macrosomia is suspected following ultrasound scanning, intervention is generally preferred to 11 
awaiting spontaneous labour onset. Although currently subject to further research32, this study found 12 
that induction of labour is the preferred intervention. However, it is worth noting that from the 13 
infant’s perspective alone, the best option is an elective caesarean section (Table S4, scenario 14 
“Maternal QALYs excluded”). 15 
Universal (rather than selective) ultrasound coupled with induction of labour has the potential to be 16 
the most cost-effective policy, but only at very high valuations of health gain: the small added benefit 17 
does not currently justify the cost. Sensitivity analysis shows that the relative cost-effectiveness of the 18 
policies is sensitive to changes in the cost of ultrasound scanning, as well as the costs of caesarean 19 
section and induction of labour, and the sensitivity and specificity of ultrasound scanning. Thus if the 20 
cost of the scan falls substantially in the future, a universal scanning policy could be cost-effective; 21 
analysis shows that this would happen at a cost lower than £26.56 (a cost reduction by 74.4%). Further, 22 
macrosomia is not the only fetal complication that can be assessed through ultrasound screening, thus 23 
when combined with a scan for other anomalies, such as breech presentation, the marginal cost of 24 
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detecting macrosomia may be sufficiently low to render the overall policy cost-effective. However, 1 
further work is needed to explore this. 2 
Strengths and Limitations 3 
The strength of this study is that it evaluates strategies for both detection and management of fetal 4 
macrosomia jointly. There has been a lack of studies evaluating screening strategies coupled with clear 5 
evidence-based interventions. Economic modelling allows us to estimate how neonatal and maternal 6 
health outcomes would be affected if ultrasound screening were to be routinely implemented in 7 
clinical practice. However, the robustness of the conclusions are only as strong as the data available 8 
to inform them. Indeed, many parameters were informed by a single study, and where no data were 9 
available we relied on expert opinion. Critically, as a part of this process we elicited a range of plausible 10 
values to represent the inherent uncertainty. The probabilistic sensitivity analysis incorporates this 11 
uncertainty to determine how much it affects the overall results. 12 
We have limited our analysis to nulliparous women. It is unclear whether our findings could be 13 
extended to parous women as well, especially given the absence of data on screening performance 14 
for universal and selective ultrasound for this group. The economic modelling also relies upon 15 
simplifying assumptions regarding the long-term outcomes from the mode of delivery and fetal 16 
delivery outcomes and did not take account of alterations to planned place of birth following 17 
ultrasound. The interplay between fetal macrosomia and long-term outcomes may be too complex to 18 
capture entirely within our model; macrosomia can lead to more complications than those explored 19 
in this analysis. However, in the absence of more detailed data on many of these complications, this 20 
model is still based upon the best current understanding of macrosomia and its consequences. 21 
The probability of delivery outcomes in this analysis relied upon the assumption of no interaction 22 
between macrosomia and the intervention. In reality, this assumption may not hold perfectly; for 23 
example, elective caesarean section may yield a greater relative risk reduction for babies with 24 
macrosomia. However, data limitations made the assumption necessary in order to model the 25 
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relevant outcomes, especially given the many different sources used for parameters. Also, the relative 1 
risk associated with both macrosomia and interventions were included in the analysis, even though 2 
interactions were not modelled. 3 
Interpretations 4 
Our conclusion that universal ultrasound screening for fetal macrosomia is not cost-effective aligns 5 
with previous findings for macrosomia management based upon ultrasound screening.10 Universal 6 
ultrasound screening strategies were less cost-effective than selective ultrasound for all scenarios. 7 
Our analysis demonstrated that universal ultrasound is associated with improved health outcomes, 8 
but that these gains are too small to justify its added cost. 9 
This analysis is based in a UK NHS setting. The results will be generalisable to other settings with similar 10 
management policies and relative costs: current UK practice is to offer a scan at first and second 11 
trimester but only offer late pregnancy scans where clinically indicated (our ‘selective ultrasound’ 12 
policy). Many European countries perform a third scan around 32 weeks.33 Diagnostic effectiveness at 13 
32 weeks for predicting complications related to macrosomia at delivery is likely to be poorer than at 14 
the 36-7 weeks assumed in our analysis, given the longer interval between the scan and timing of 15 
birth.16 This would suggest earlier scans are even less likely to be cost-effective. 16 
As stated above, the impact of caesarean section (CS) on maternal quality of life was a key driver of 17 
the results. To the best of our knowledge, the study by Petrou et al.27 is the only study that reports 18 
maternal quality of life (QOL) as a function of the mode of delivery, using an adequate time horizon 19 
and a measure for QOL recommended by NICE.29 However, it reported lower QOL for women who 20 
underwent elective CS than their counterparts who delivered through emergency CS, a finding that 21 
appears counterintuitive. If maternal QOL had been higher following elective CS than emergency CS, 22 
the economic analysis would have been more favourable towards policies with planned CS. Against 23 
this should be weighted the research that has shown that caesarean section is associated with 24 
increased risk of a range of complications in subsequent pregnancies.34-36 These risks are not captured 25 
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in our simulation model since the perspective was for the current pregnancy, but implies that 1 
managing suspected macrosomia through planned CS may be more detrimental than suggested in this 2 
analysis. 3 
This analysis has compared interventions based upon suspicion of macrosomia alone. However, in 4 
clinical practice more factors influence antenatal management than just whether ultrasound 5 
screening indicates fetal macrosomia. This analysis offer valuable information for policymaking, but it 6 
does not rule out the use of planned CS or expectant management in individual cases. 7 
  8 
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Conclusion 1 
Universal ultrasound scanning in the third trimester is not cost-effective at detecting macrosomia in 2 
nulliparous women at current UK cost-effectiveness threshold limits. If fetal macrosomia is suspected 3 
following ultrasound, induction of labour is likely to be the most cost-effective management option. 4 
The conclusions are based on a single scan for macrosomia alone. A strategy that combines scanning 5 
for macrosomia with other conditions, e.g. breech presentation (and growth restriction), might be 6 
cost-effective. Future research should focus on whether joint screening for multiple fetal 7 
complications would be cost-effective, as well as on the long-term health consequences from delivery 8 
outcomes, especially how maternal health is affected by the mode of delivery.  9 
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Tables & Figures 
Figure 1: Structure of simulation model. 
The figure shows the model structure, from screening to long-term health outcomes. Part A (left) shows the pathway from screening to the mode of delivery. When 
macrosomia is suspected (“T+”), the mode of delivery depends on the management strategy as shown in part B (middle). Part C (right) shows the different delivery 
outcomes, and their associated long-term outcomes. 
CS = Caesarean section; BPI = Brachial plexus injury; D+ = disease positive; D- = Disease negative; T+ = Test positive; T- = Test negative.  
23 
 
Figure 2: Cost-effectiveness acceptability curve for policies for detection and management of fetal macrosomia. 
Cost-effectiveness acceptability curve (CEAC) showing the chance for each policy of being the most cost-effective for different levels of willingness-to-pay 
(WTP). Policies with universal ultrasound are shown as dashed lines and selective ultrasound as solid. Higher values for WTP implies a higher valuation of a 
quality-adjusted life year (QALY). The conventional WTP-thresholds for cost-effectiveness is £20,000 to £30,000 (marked in figure).29 
CS = Caesarean section. 
